Evidence map›Paper›PMID 39877599›Full record

ArticleHeliyon2025

Is an oritavancin catheter lock solution active against biofilms of staphylococci and enterococci?

Marta Díaz-Navarro, Emilia Cercenado, Ariadna Monte, Andrés Visedo, Carmen Rodríguez, Ma Jesús Pérez-Granda, Patricia Muñoz, María Guembe

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Heliyon, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Marta Díaz-NavarroDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Emilia CercenadoDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Ariadna MonteSchool of Biology, Universidad Complutense de Madrid, Spain.
Andrés VisedoDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Carmen RodríguezPharmacy Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Ma Jesús Pérez-GrandaDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
Patricia MuñozDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.
María GuembeDepartment of Clinical Microbiology and Infectious Diseases, Hospital General Universitario Gregorio Marañón, Madrid, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Oritavancin (ORT) is a new single-dose lipoglycopeptide showing Methods: We used Results: The percentage reduction in metabolic activity was 95.3 % between biofilms treated with ORT solution incubated for 7 days and biofilms treated with ORT solution before incubation. Conclusion: Ours is a proof-of-concept study that shows ORT to be a potential treatment as a catheter lock solution for eradication of staphylococcal and

Indexed as

ActivityCatheter lock solutionCatheter-related bloodstream infectionOritavancinStability

Identifiers

PMID39877599
PMCPMC11773058

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.